Search

Savara Inc

Chiusa

SettoreSettore sanitario

4.63 -1.49

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.61

Massimo

4.74

Metriche Chiave

By Trading Economics

Entrata

-2.8M

-43M

EPS

-0.17

Dipendenti

70

EBITDA

-3.4M

-43M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+158.62% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

63M

1B

Apertura precedente

6.12

Chiusura precedente

4.63

Savara Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 nov 2026, 00:01 UTC

Savara Inc. saw a modest increase in after-market trading, recovering from a low point earlier in the session.

13 nov 2026, 21:03 UTC

Savara Inc. shares are declining, reversing a trend of higher daily closes since Thursday, amid unusually high market volume today.

12 nov 2026, 22:01 UTC

News

Savara Inc. grants inducement awards to seven new employees, including options for 20.5k shares at an exercise price of $4.92 per share.

11 nov 2026, 21:02 UTC

News

Savara Inc. is advancing in price ahead of its PDUFA date on November 22, with unusually high trading volume attracting investor interest.

10 nov 2026, 21:07 UTC

Savara Inc. shares fell sharply, reversing earlier gains to close significantly below their opening level, reaching their lowest point in the afternoon.

9 nov 2026, 23:41 UTC

Savara Inc. is trading higher in after-market hours, reaching its highest cumulative return since Monday's close and maintaining strong upward momentum.

6 nov 2026, 21:02 UTC

Savara Inc. shares are advancing, showing a significant increase since Thursday's close, with unusually high trading volume despite earlier pulling back from a session high.

5 nov 2026, 21:04 UTC

Correlated Moves

Savara Inc. shares fell sharply, reflecting a broader decline in the biotechnology sector, as the SPDR S&P Biotech ETF also experienced significant losses.

4 nov 2026, 20:52 UTC

Savara Inc. shares fell sharply, remaining below their 20-day moving average amid unusually high market volume and significant fluctuations earlier in the session.

3 nov 2026, 21:07 UTC

Savara Inc. shares are advancing, building on Monday's close, despite pulling back from an earlier session high amid overall modest market gains.

2 nov 2026, 23:06 UTC

Savara Inc. shares advanced in after-market trading, gaining ground since Monday's close, following three consecutive sessions that finished lower.

30 ott 2026, 20:08 UTC

Savara Inc. shares fell significantly, reflecting broader market weakness, and finished notably lower compared to Thursday's close.

29 ott 2026, 20:06 UTC

Savara Inc. shares fell sharply as the broader market closed lower after an early peak.

28 ott 2026, 20:02 UTC

Savara Inc. shares are advancing, diverging from a broader market downturn observed during Wednesday's session.

27 ott 2026, 21:01 UTC

Savara Inc. shares declined modestly in after-market trading, remaining near the bottom of their range after a notable drop earlier in the session.

26 ott 2026, 23:56 UTC

Savara Inc's shares advanced in after-market trading, reflecting a notable rise since Monday's close, though still below its 20-day moving average.

23 ott 2026, 21:02 UTC

Savara Inc shares advanced in after-market trading, reaching a high shortly after the market closed before settling to a more modest gain.

22 ott 2026, 20:07 UTC

News

Savara Inc's stock is declining after the company reiterated its Market Outperform rating and $10 price target, following new Molbreevi data presented at the CHEST conference.

21 ott 2026, 23:16 UTC

Savara Inc is trading higher in after-market hours, gaining since Wednesday's close.

20 ott 2026, 23:06 UTC

Savara Inc. shares advanced modestly in after-market hours, following a session that saw earlier peak gains before settling lower.

19 ott 2026, 22:51 UTC

Savara Inc shares are moving higher in after-market trading, supported by an upward trend in the broader market, despite earlier session pullbacks.

16 ott 2026, 22:26 UTC

Savara Inc shares traded lower in after-market hours, reflecting ongoing weakness amid broader market concerns over rising U.S. import and export prices.

15 ott 2026, 23:06 UTC

Savara Inc's shares are advancing in after-market trading, gaining ground since Thursday's close, with a cumulative return peaking at just under 1.9%.

14 ott 2026, 19:36 UTC

Savara Inc shares fell modestly on Wednesday, retracing from an early peak and remaining under pressure below their 20-day moving average.

13 ott 2026, 20:13 UTC

Savara Inc shares advanced in after-market trading, continuing their upward trend since Tuesday's close, though still below the 20-day moving average.

12 ott 2026, 19:36 UTC

Social Media

Savara Inc shares are declining, having pulled back from an earlier high in pre-market hours, and are currently below their 20-day moving average.

9 ott 2026, 19:55 UTC

Social Media

JPMorgan sets a price target of $12 for Savara Inc, noting catalysts including anticipated UK approval in Q4 and a MAA in Q1 for molgramostim.

8 ott 2026, 23:25 UTC

Savara Inc shares advanced during after-market hours on Thursday, settling at a solid gain.

7 ott 2026, 20:01 UTC

News
Social Media

Savara Inc shares are trading sharply higher as JP Morgan initiated coverage with an Overweight rating and a $12 price target ahead of its PDUFA date.

6 ott 2026, 20:00 UTC

Savara Inc shares fell, breaking a trend of higher daily closes, indicating a shift in momentum following Monday's close.

Confronto tra pari

Modifica del prezzo

Savara Inc Previsione

Obiettivo di Prezzo

By TipRanks

158.62% in crescita

Previsioni per 12 mesi

Media 12 USD  158.62%

Alto 16 USD

Basso 10 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Savara Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

5

Acquista

0

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat